论文信息 - The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression. - 字舞流文

The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression.

Y. Miyagi | T. Hasegawa | K. Sakai | A. Hasegawa | A. Aikawa | S. Mizuiri | Y. Itabashi | M. Muramatsu | T. Ohara | T. Kawamura | K. Arai | K. Sugiyama

[1] W. A. Jurewicz. Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2] H. E. Hansen,et al. The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[3] M. Hall,et al. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. , 1999, Transplantation.

[4] P. Nickerson,et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. , 1998, Journal of the American Society of Nephrology : JASN.

[5] G. Remuzzi,et al. Basiliximab. Point of view , 1999 .